CCL7 Chemokine Is a Marker but Not a Therapeutic Target of Acute Kidney Injury
Nephron · 2024
DOI: 10.1159/000536411 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nephron, 2024. Verfasst von Audrey Casemayou und 9 weiteren Autor:innen. Beteiligte Einrichtung: Département de Néphrologie et Transplantation d'Organes, Centre de référence des maladies rénales rares (SORARE), French Intensive Care Renal Network…. Hauptthemen laut MEDLINE: Acute Kidney Injury, Chemokine CCL7, Mice, Knockout. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 14 Literaturangaben.
Abstract (Originalsprache)
Background
Chemokines orchestrate immune cells activation and infiltration during acute kidney injury (AKI).
Objectives
We aim to test whether deletion of C-C chemokine ligand 7 (CCL7), a small chemokine related to CCL2 (MCP-1), may modulate AKI development and progression toward kidney fibrosis.
Method
Expression of CCL7 was quantified in murine cortical tubular (MCT) cells exposed to myoglobin or lipopolysaccharide or submitted to metabolic reprogramming. Kidney function (BUN, glomerular filtration rate), expression of CCL7 receptors, and kidney infiltration by inflammatory cells (F4/80+ macrophages, MPO+ neutrophils, and B220+ B-cells) were assessed in wt and Ccl7−/− mice submitted to 3 different models of AKI or kidney fibrosis (uni/bilateral ischemia/reperfusion injury (u/bIRI) and rhabdomyolysis).
Results
Toxin exposure of MCT cells, as well as metabolic reprogramming recapitulating AKI changes, led to a dramatic up-regulation of CCL7. In vivo, kidney expression of Ccl7 and Ccl2 significantly increased after AKI and remained increased beyond the acute phase (30 days after uIRI). The expression of the CCL7 receptors was heterogeneous and varied with time. Kidney function, expression of CCL7 receptors and Ccl2, and the number of inflammatory cells within kidneys were similar in wt and Ccl7−/− mice at baseline and at day 2 after AKI. Thirty days after uIRI, kidney fibrosis was similar in both mouse strains.
Conclusions
Despite strong induction of CCL7 after AKI, CCL7 deficiency does not prevent AKI and the transition toward kidney fibrosis and should probably not be further explored as a potential target to prevent or treat AKI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Département de Néphrologie et Transplantation d'Organes, Centre de référence des maladies rénales rares (SORARE), French Intensive Care Renal Network (FIRN), University Hospital of Toulouse, Toulouse, France.
- Institut National de la Santé et de la Recherche Médicale (INSERM), U1297, Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse, France.
- Faculté de Médecine, Université Toulouse III Paul-Sabatier, Toulouse, France.
- Service d'explorations physiologiques fonctionnelles, Centre hospitalier universitaire de Toulouse, Toulouse, France.
Zitieren
APA
Casemayou, A., Piedrafita, A., Engel, R., Feuillet, G., Alves, M., Tack, I., Klein, J., Buleon, M., Schanstra, J. P., & Faguer, S. (2024). CCL7 Chemokine Is a Marker but Not a Therapeutic Target of Acute Kidney Injury. Nephron. https://doi.org/10.1159/000536411
Vancouver
Casemayou A, Piedrafita A, Engel R, Feuillet G, Alves M, Tack I, et al. CCL7 Chemokine Is a Marker but Not a Therapeutic Target of Acute Kidney Injury. Nephron. 2024. doi:10.1159/000536411
BibTeX
@article{Casemayou2024,
author = {Casemayou, Audrey and Piedrafita, Alexis and Engel, Rémi and Feuillet, Guylène and Alves, Melinda and Tack, Ivan and Klein, Julie and Buleon, Marie and Schanstra, Joost P and Faguer, Stanislas},
title = {CCL7 Chemokine Is a Marker but Not a Therapeutic Target of Acute Kidney Injury},
journal = {Nephron},
year = {2024},
doi = {10.1159/000536411}
}
EUVIMED